Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In patients with metastatic breast cancer that is positive for human epidermal growth factor receptor 2 (HER2), progression-free survival was significantly improved after first-line therapy with pertuzumab, trastuzumab, and docetaxel, as compared with placebo, trastuzumab, and docetaxel. Overall survival was significantly improved with pertuzumab in an interim analysis without the median being reached. We report final prespecified overall survival results with a median follow-up of 50 months. METHODS: We randomly assigned patients with metastatic breast cancer who had not received previous chemotherapy or anti-HER2 therapy for their metastatic disease to receive the pertuzumab combination or the placebo combination. The secondary end points of overall survival, investigator-assessed progression-free survival, independently assessed duration of response, and safety are reported. Sensitivity analyses were adjusted for patients who crossed over from placebo to pertuzumab after the interim analysis. RESULTS: The median overall survival was 56.5 months (95% confidence interval [CI], 49.3 to not reached) in the group receiving the pertuzumab combination, as compared with 40.8 months (95% CI, 35.8 to 48.3) in the group receiving the placebo combination (hazard ratio favoring the pertuzumab group, 0.68; 95% CI, 0.56 to 0.84; P<0.001), a difference of 15.7 months. This analysis was not adjusted for crossover to the pertuzumab group and is therefore conservative. Results of sensitivity analyses after adjustment for crossover were consistent. Median progression-free survival as assessed by investigators improved by 6.3 months in the pertuzumab group (hazard ratio, 0.68; 95% CI, 0.58 to 0.80). Pertuzumab extended the median duration of response by 7.7 months, as independently assessed. Most adverse events occurred during the administration of docetaxel in the two groups, with long-term cardiac safety maintained. CONCLUSIONS: In patients with HER2-positive metastatic breast cancer, the addition of pertuzumab to trastuzumab and docetaxel, as compared with the addition of placebo, significantly improved the median overall survival to 56.5 months and extended the results of previous analyses showing the efficacy of this drug combination. (Funded by F. Hoffmann-La Roche and Genentech; CLEOPATRA ClinicalTrials.gov number, NCT00567190.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“the safety and efficacy profiles for SC trastuzumab in combination with IV pertuzumab and docetaxel as a first-line treatment for patients with HER2-positive MBC in the MetaPHER study (NCT02402712) was found to be consistent with those observed for IV trastuzumab in combination with IV pertuzumab and docetaxel in the CLEOPATRA study (NCT00567190) [21, 35–38].”
From A systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting (2023) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Self-citationPertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
Self-citationGianni, L., Pienkowski, T., Im, Y.-H., Roman, L., Tseng, L.-M., Liu, M.-C., Lluch, A., Staroslawska, E., de la Haba-Rodriguez, J., Im, S.-A., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70336-9 · Cited by 2,374
Self-citationSmith, T. J., Khatcheressian, J., Lyman, G. H., Ozer, H., Armitage, J. O., Balducci, L., Bennett, C. L., Cantor, S. B., Crawford, J., Cross, S. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.4451 · Cited by 1,636
Marty, M., Cognetti, F., Maraninchi, D., Snyder, R., Mauriac, L., Tubiana-Hulin, M., Chan, S., Grimes, D., Antón, A., Lluch, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.173 · Cited by 1,597
Ross, J. S., Slodkowska, E. A., Symmans, W. F., Pusztai, L., Ravdin, P. M., & Hortobagyi, G. N. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0230 · Cited by 1,144
Swain, S. M., Kim, S.-B., Cortés, J., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Knott, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70130-x · Cited by 1,006
Self-citationvon Minckwitz, G., du Bois, A., Schmidt, M., Maass, N., Cufer, T., de Jongh, F. E., Maartense, E., Zielinski, C., Kaufmann, M., Bauer, W., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6618 · Cited by 676
Baselga, J., Gelmon, K. A., Verma, S., Wardley, A., Conte, P., Miles, D., Bianchi, G., Cortes, J., McNally, V. A., Ross, G. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2024 · Cited by 643
Self-citation
Cited by
Items 601–700 of 1,001
Ono, H., Iizumi, Y., Goi, W., Sowa, Y., Taguchi, T., & Sakai, T. (2017) · Oncology Reports · doi:10.3892/or.2017.6008 · Cited by 29
Tao, J., Tan, Z., Diao, L., Ji, Z., Zhu, J., Chen, W., & Hu, Y. (2018) · RSC Advances · doi:10.1039/c8ra02833h · Cited by 27
Zhang, J., Zhang, Y., Tang, S., Jiang, L., He, Q., Hamblin, L. T., He, J., Xu, Z., Wu, J., Chen, Y., et al. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-017240 · Cited by 27
Oligoclonal selection of nanobodies targeting vascular endothelial growth factor
Ahadi, M., Ghasemian, H., Behdani, M., & Kazemi‐Lomedasht, F. (2018) · Journal of Immunotoxicology · doi:10.1080/1547691x.2018.1526234 · Cited by 28
Current state of clinical trials in breast cancer brain metastases
Fares, J., Kanojia, D., Cordero, Á., Rashidi, A., Miska, J. M., Schwartz, C. W., Savchuk, S., Ahmed, A. U., Balyasnikova, I. V., Cristofanilli, M., et al. (2019) · Neuro-Oncology Practice · doi:10.1093/nop/npz003 · Cited by 28
Nami, B., Maadi, H., & Wang, Z. (2019) · Cancers · doi:10.3390/cancers11030375 · Cited by 27
Quantification of Trastuzumab–HER2 Engagement In Vitro and In Vivo
Rudkouskaya, A., Smith, J. T., Intes, X., & Barroso, M. (2020) · Molecules · doi:10.3390/molecules25245976 · Cited by 30
Li, W., Li, S., Chen, I. X., Liu, Y., Ramjiawan, R. R., Leung, S. C. H., Gerweck, L. E., Fukumura, D., Loeffler, J. S., Jain, R. K., et al. (2021) · Radiation Oncology · doi:10.1186/s13014-021-01775-9 · Cited by 32
Cardiac Toxicity Associated with Cancer Immunotherapy and Biological Drugs
Montisci, A., Vietri, M. T., Palmieri, V., Sala, S., Donatelli, F., & Napoli, C. (2021) · Cancers · doi:10.3390/cancers13194797 · Cited by 28
Jiang, N., Saftics, A., Romano, E., Ghaeli, I., Resto, C., Robles, V. M., Das, S., Keuren‐Jensen, K. R. V., Seewaldt, V. L., & Jovanović‐Talisman, T. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02858-x · Cited by 30
Dieras, V. C., Curigliano, G., Martín, M., Lerebours, F., Tsurutani, J., Savard, M.-F., Jerzak, K. J., Hu, X., Pimentel, L. C. M. D. A., O'Sullivan, C. C., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-02600 · Cited by 29
Lambertini, M., Ferreira, A. R., Poggio, F. B., Puglisi, F., Bernardo, A., Montemurro, F., Poletto, E., Pozzi, E., Rossi, V., Risi, E., et al. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0020 · Cited by 26
Current and emerging therapies of HER2-positive metastatic breast cancer
Hernández-Blanquisett, A., Touya, D., Strasser‐Weippl, K., Ruiz, R., Louis, J. S., & Goss, P. E. (2016) · The Breast · doi:10.1016/j.breast.2016.07.026 · Cited by 30
Daniels, B. J., Kiely, B. E., Lord, S. J., Houssami, N., Lu, C. Y., Ward, R. L., & Pearson, S. (2017) · The Breast · doi:10.1016/j.breast.2017.11.007 · Cited by 26
Pereira, P. M. R., Abma, L., Henry, K. E., & Lewis, J. S. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.052 · Cited by 27
Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D)
Moreno‐Aspitia, A., Holmes, E. M., Jackisch, C., de Azambuja, E., Boyle, F. M., Hillman, D. W., Korde, L. A., Fumagalli, D., Izquierdo, M. A., McCullough, A. E., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.01.053 · Cited by 25
Self-citationZhang, J., Meng, Y., Wang, B., Wang, L., Cao, J., Tao, Z., Li, T., Yao, W., & Hu, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.775081 · Cited by 28
New Insights on the Toxicity on Heart and Vessels of Breast Cancer Therapies
Lanza, O., Ferrera, A., Reale, S., Solfanelli, G., Petrungaro, M., Tini, G., Volpe, M., & Battistoni, A. (2022) · Medical Sciences · doi:10.3390/medsci10020027 · Cited by 26
Newly Approved and Emerging Agents in HER2-Positive Metastatic Breast Cancer
Graff, S. L., Yan, F., & Abdou, Y. G. (2023) · Clinical Breast Cancer · doi:10.1016/j.clbc.2023.05.003 · Cited by 27
Fallowfield, L. J., Catt, S. L., May, S. F., Matthews, L., Shilling, V. M., Simcock, R., Westwell, S., & Jenkins, V. A. (2017) · Supportive Care in Cancer · doi:10.1007/s00520-016-3408-7 · Cited by 25
Aref‐Eshghi, E., Abadi, A., Farhadieh, M., Hooshmand, A., Ghasemi, F., Youssefian, L., Vahidnezhad, H., Kerrins, T. M., Zhao, X., Akbarzadeh, M., et al. (2025) · Clinical Epigenetics · doi:10.1186/s13148-025-01967-0 · Cited by 31
Araki, K., Fukada, I., Yanagi, H., Kobayashi, K., Shibayama, T., Horii, R., Takahashi, S., Akiyama, F., Ohno, S., & Ito, Y. (2017) · The Breast · doi:10.1016/j.breast.2017.06.015 · Cited by 25
Henry, K. E., Ulaner, G. A., & Lewis, J. S. (2018) · PET Clinics · doi:10.1016/j.cpet.2018.02.010 · Cited by 25
Towards precision oncology for HER2 blockade in gastroesophageal adenocarcinoma
Gambardella, V., Fleitas, T., Tarazona, N., Cejalvo, J. M., Gimeno-Valiente, F., Martínez‐Ciarpaglini, C., Huerta, M., Roselló, S., Castillo, J., Roda, D., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz143 · Cited by 27
Yan, S., Wang, W., Zhu, B., Pan, X., Wu, X., & Tao, W. (2020) · Cancer Management and Research · doi:10.2147/cmar.s270687 · Cited by 25
Developments in the Management of Metastatic HER2-Positive Breast Cancer: A Review
Lebert, J. M., & Lilly, E. J. (2022) · Current Oncology · doi:10.3390/curroncol29040208 · Cited by 29
Krutilina, R. I., Hartman, K. L., Oluwalana, D., Playa, H. C., Parke, D. N., Chen, H., Miller, D. D., Li, W., & Seagroves, T. N. (2022) · Cancers · doi:10.3390/cancers14215336 · Cited by 26
Zheng, Y., Cao, W., Shao, X., Shi, Y., Cai, L., Chen, W., Liu, J., Shen, P., Chen, Y., Wang, X., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-44140-y · Cited by 30
Gómez, H., Neciosup, S. P., Tosello, C., Mano, M. S., Bines, J., Ismael, G., Santi, P. X., Pinczowski, H., Nerón, Y. V., Fanelli, M. F., et al. (2015) · Clinical Breast Cancer · doi:10.1016/j.clbc.2015.10.005 · Cited by 25
Nonagase, Y., Yonesaka, K., Kawakami, H., Watanabe, S., Haratani, K., Takahama, T., Takegawa, N., Ueda, H., Tanizaki, J., Hayashi, H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12743 · Cited by 28
Koleva‐Kolarova, R., Oktora, M. P., Robijn, A. L., Greuter, M. J. W., Reyners, A. K. L., Buskens, E., & de Bock, G. H. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.01.001 · Cited by 25
Bentley, T. G. K., Cohen, J. T., Elkin, E. B., Huynh, J., Mukherjea, A., Neville, T. H., Mei, M. G., Copher, R. M., Knoth, R. L., Popescu, I., et al. (2017) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2017.23.6-a.s34 · Cited by 31
Ambrosetti, E., Paoletti, P., Bosco, A., Parisse, P., Scaini, D., Tagliabue, E., de Marco, A., & Casalis, L. (2017) · ACS Omega · doi:10.1021/acsomega.7b00284 · Cited by 25
Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer
Pezo, R. C., Chen, T. W., Berman, H. K., Mulligan, A. M., Razak, A. A., Siu, L. L., Cescon, D. W., Amir, E., Elser, C., Warr, D. G., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4580-2 · Cited by 27
Mahtani, R. L., Holmes, F. A., Badve, S., Caldera, H., Coleman, R. E., Mamounas, E. P., Kalinsky, K. M., Kittaneh, M., Lower, E. E., Pegram, M. D., et al. (2019) · Clinical Breast Cancer · doi:10.1016/j.clbc.2019.08.001 · Cited by 25
Biosimilars in oncology: Effects on economy and therapeutic innovations
Hübel, K., Kron, F., & Lux, M. P. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.07.037 · Cited by 25
Jiang, Z., Song, E., Wang, X., Wang, H., Wang, X., Wu, J., Yin, Y., Zhang, Q., Chen, J., Che, W., et al. (2020) · Translational Breast Cancer Research · doi:10.21037/tbcr-2020-2 · Cited by 32
Linehan, A., Fitzpatrick, O. M., & Morris, P. G. (2021) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s245024 · Cited by 27
Role and regulation of FOXO3a: new insights into breast cancer therapy
Mei, W., Mei, B., Chang, J., Liu, Y., Zhou, Y., Zhu, N., & Hu, M. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1346745 · Cited by 32
Impact of Molecular Profiling on Therapy Management in Breast Cancer
Ultimescu, F., Hudiță, A., Popa, D. E., Olincă, M., Muresean, H. A., Ceaușu, M. C., Stanciu, D. I., Ginghină, O., & Gălățeanu, B. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13174995 · Cited by 26
Tiwari, S. R., Mishra, P. J., Raska, P., Calhoun, B. C., Abraham, J., Moore, H. C. F., Budd, G. T., Fanning, A., Valente, S. A., Stewart, R., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3866-0 · Cited by 24
Application of E75 peptide vaccine in breast cancer patients: A systematic review and meta-analysis
Chamani, R., Ranji, P., Hadji, M., Nahvijou, A., Esmati, E., & Alizadeh, A. M. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.05.010 · Cited by 24
Optimized EGFR Blockade Strategies in EGFR Addicted Gastroesophageal Adenocarcinomas
Corso, S., Pietrantonio, F., Apicella, M., Migliore, C., Conticelli, D., Petrelli, A., D’Errico, L., Durando, S., Moya‐Rull, D., Bellomo, S. E., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0121 · Cited by 25
Potential molecular mechanisms and clinical progress in liver metastasis of breast cancer
Liu, H., Li, X., Li, H., Feng, L., Sun, G., Sun, G., Wu, L., Hu, Y. H., Liu, L., & Wang, H. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112824 · Cited by 28
Therapeutic Landscape of Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
Xie, J., Zou, Y., Gao, T., Xie, L., Tan, D., & Xie, X. (2022) · Cancer Control · doi:10.1177/10732748221099230 · Cited by 32
Asgari-Karchekani, S., Aryannejad, A., Mousavi, S. A., Shahsavarhaghighi, S., & Tavangar, S. M. (2022) · Medical Oncology · doi:10.1007/s12032-022-01817-6 · Cited by 24
Local γδ T cells: translating promise to practice in cancer immunotherapy
Zlatareva, I., & Wu, Y. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02303-0 · Cited by 27
Zou, S., Yang, H.-Y., Ouyang, M., Cheng, Q., Shi, X., & Sun, M. (2023) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-023-00702-w · Cited by 24
Personalized treatment approach for HER2-positive metastatic breast cancer
Pandey, P., Chaudhary, R., Tripathi, D., Lavudi, K., Dua, K., Weinfeld, M., Lavasanifar, A., & Rajinikanth, P. S. (2024) · Medical Oncology · doi:10.1007/s12032-024-02504-4 · Cited by 30
Pagani, O., Klingbiel, D., Ruhstaller, T., Nolè, F., Eppenberger, S., Oehlschlegel, C., Bernhard, J., Brauchli, P., Hess, D., Mamot, C., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw622 · Cited by 24
Quartino, A. L., Li, H., Jin, J. Y., Wada, D., Benyunes, M. C., McNally, V. A., Viganò, L., Nijem, I., Lum, B. L., & Garg, A. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3218-0 · Cited by 26
Self-citationThe Use of Immunotherapy to Treat Metastatic Breast Cancer
Nicolini, A., Barak, V., Biava, P. M., Ferrari, P., Rossi, G., & Carpi, A. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180209124052 · Cited by 27
Gu, S., Ngamcherdtrakul, W., Reda, M. M., Hu, Z., Gray, J. W., & Yantasee, W. (2018) · PLoS ONE · doi:10.1371/journal.pone.0198141 · Cited by 25
van Rooijen, J. M., Qiu, S.-Q., Timmer‐Bosscha, H., van der Vegt, B., Boers, J. E., Schröder, C. P., & de Vries, E. G. E. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.08.001 · Cited by 24
Tsai, Y., Tseng, L., Lien, P., Hsu, C., Lin, Y., King, K., Wang, Y., Chao, T., Liu, C., Chiu, J., et al. (2018) · Histopathology · doi:10.1111/his.13801 · Cited by 24
On behalf of the Nicht-interventionelle Untersuchung (NIU) HER2 Study Group, Baretton, G. B., Kreipe, H. H., Schirmacher, P., Gaiser, T., Hofheinz, R., Berghäuser, K.-H., Koch, W., Künzel, C., Morris, S., et al. (2019) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-019-02541-9 · Cited by 24
Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer
Zhu, J., Tucker, M. D., Marin, D., Gupta, R. T., Healy, P. N., Humeniuk, M. S., Jarvis, C., Zhang, T., McNamara, M. A., George, D. J., et al. (2019) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2019.06.015 · Cited by 25
Collin, L. J., Jiang, R., Ward, K. C., Gogineni, K., Subhedar, P. D., Sherman, M. E., Gaudet, M. M., Breitkopf, C. R., D’Angelo, O., Gabram‐Mendola, S., et al. (2019) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkz053 · Cited by 26
Current Development of Monoclonal Antibodies in Cancer Therapy
Parakh, S., King, D., Gan, H. K., & Scott, A. M. (2019) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-030-23765-3_1 · Cited by 28
Dessie, Z. G., & Zewotir, T. T. (2025) · BMC Public Health · doi:10.1186/s12889-025-24036-w · Cited by 27
Hatch, A. J., Sibley, A. B., Starr, M. D., Brady, J. C., Jiang, C., Jia, J., Bowers, D. L., Pang, H., Owzar, K., Niedzwiecki, D., et al. (2016) · Cancer Medicine · doi:10.1002/cam4.806 · Cited by 24
Okines, A. F. C., Irfan, T., Khabra, K., Smith, I., O'Brien, M. E. R., Parton, M., Noble, J., Stanway, S., Somaiah, N., Ring, A. E., et al. (2017) · The Breast Journal · doi:10.1111/tbj.12906 · Cited by 24
Janni, W., Schneeweiß, A., Müller, V., Wöckel, A., Lux, M. P., Hartkopf, A. D., Nabieva, N., Taran, F., Tesch, H., Overkamp, F., et al. (2019) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-0842-6661 · Cited by 23
Prevention, Detection, and Management of Heart Failure in Patients Treated for Breast Cancer
Månsson‐Broberg, A., Geisler, J., TUOHINEN, S. S., Skyttä, T., Hrafnkelsdóttir, Þ. J., Nielsen, K. M., Hedayati, E., Omland, T., Offersen, B. V., Lyon, A. R., et al. (2020) · Current Heart Failure Reports · doi:10.1007/s11897-020-00486-8 · Cited by 28
Jeong, H., Jeong, J. H., Kim, K., Lee, S. S., Oh, D., Park, D. H., Song, T. J., Park, Y., Hong, S., Ryoo, B., et al. (2021) · Cancers · doi:10.3390/cancers13020161 · Cited by 24
Modi, N. D., Danell, N. O., Perry, R. N. A., Abuhelwa, A. Y., Rathod, A., Badaoui, S., McKinnon, R. A., Haseloff, M., Shahnam, A., Swain, S. M., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100475 · Cited by 28
Self-citationShao, Y., Luo, Z., Yu, Y., Chen, Q., He, Y., Liu, C., Nie, B., Zhu, F., & Liu, H. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1000704 · Cited by 25
Different treatment regimens in breast cancer visceral crisis: A retrospective cohort study
Yang, R., Lu, G., Lv, Z., Jia, L., & Cui, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1048781 · Cited by 25
Javid, H., Attarian, F., Saadatmand, T., Rezagholinejad, N., Mehri, A., Amiri, H., & Karimi‐Shahri, M. (2023) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30402 · Cited by 23
Pertuzumab for the treatment of breast cancer: a safety review
Gao, J. J., & Swain, S. M. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1167185 · Cited by 23
Self-citationVasista, A., Stockler, M. R., West, T. A., Wilcken, N., & Kiely, B. E. (2016) · The Breast · doi:10.1016/j.breast.2016.10.007 · Cited by 24
Current Trends in Cancer Therapy
Sekhon, N., Kumbla, R. A., & Mita, M. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803547-4.00001-x · Cited by 30
Prognostic role of Gli1 expression in breast cancer: a meta-analysis
Wang, B., Yu, T., Hu, Y., Xiang, M., Peng, H., Lin, Y., Han, L., & Zhang, L. (2017) · Oncotarget · doi:10.18632/oncotarget.19080 · Cited by 26
Daniels, B. J., Kiely, B. E., Lord, S. J., Houssami, N., Lu, C. Y., Ward, R. L., & Pearson, S. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4804-0 · Cited by 23
SEOM clinical guidelines in advanced and recurrent breast cancer (2018)
Chacón, J. I., de la Cruz‐Merino, L., Gregori, J. G., de Dueñas, E. M., Oliveira, M., Seguí, M. Á., Álvarez, I., Antolín, S., Bellet, M., & López‐Tarruella, S. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-018-02010-w · Cited by 31
Cardiomyopathies and Arrhythmias Induced by Cancer Therapies
Romitan, D.-M., Rădulescu, D., Berindan‐Neagoe, I., Stoicescu, L., Grosu, A. I., Rădulescu, L., Gulei, D., & Ciuleanu, T. (2020) · Biomedicines · doi:10.3390/biomedicines8110496 · Cited by 24
Kuemmel, S., Tondini, C. A., Abraham, J., Nowecki, Z., Itrych, B., Hitre, E., Karaszewska, B., Juárez-Ramiro, A., Morales-Vásquez, F., Pérez-García, J. M., et al. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06145-3 · Cited by 22
Self-citationNovel approaches to target HER2-positive breast cancer: trastuzumab emtansine
Leone, J. P., Recondo, G., Vega, M., Galanternik, F., Diaz-Canton, E. A., & Leone, B. A. (2016) · Cancer Management and Research · doi:10.2147/cmar.s104447 · Cited by 25
The expression of CCL18 in diffuse large B cell lymphoma and its mechanism research
Zhou, Q., Huang, L., Gu, Y., Lu, H., & Feng, Z. (2018) · Cancer Biomarkers · doi:10.3233/cbm-171097 · Cited by 22
Ahn, S. J., Park, M., Bang, S., Cho, E., Ahn, S. G., Suh, S. H., & Lee, J. (2018) · Scientific Reports · doi:10.1038/s41598-018-28315-y · Cited by 22
Pulte, D. D., Weberpals, J. G., Jansen, L., & Brenner, H. (2019) · Cancer · doi:10.1002/cncr.32160 · Cited by 22
Delrieu, L., Jacquet, E., Ségura‐Ferlay, C., Blanc, E., Febvey‐Combes, O., Friedenreich, C. M., Romieu, G., Jacot, W., Rios, M., Heudel, P., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-67431-6 · Cited by 27
Self-citationGampenrieder, S. P., Castagnaviz, V., Rinnerthaler, G., & Greil, R. (2020) · Cancer Management and Research · doi:10.2147/cmar.s235121 · Cited by 23
Zhang, L., Wu, X., Zhou, J., Zhu, M., Yu, H., Zhang, Y., Zhao, Y., Han, Z., Guo, Y., Guan, X.-Q., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.699323 · Cited by 23
Jani, C., Salciccioli, I., Rupal, A., Omari, O. A., Goodall, R., Salciccioli, J. D., Marshall, D. C., Hanbury, G., Singh, H., Weissmann, L., et al. (2021) · JCO Global Oncology · doi:10.1200/go.21.00288 · Cited by 22
Wildiers, H. P. M. W., Meyskens, T., Marreaud, S. I., Lago, L. D., Vuylsteke, P., Curigliano, G., Waters, S. H., Brouwers, B. A. H., Meulemans, B., Sousa, B., et al. (2022) · The Breast · doi:10.1016/j.breast.2022.05.004 · Cited by 25
Aiming for the Cure in ERBB2-Positive Metastatic Breast Cancer—Should We Go “All In”?—Reply
Tarantino, P., Parsons, H. A., & Tolaney, S. M. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.1922 · Cited by 22
Hyaluronan-estradiol nanogels as potential drug carriers to target ER+ breast cancer cell line
Paoletti, L., Zoratto, N., Benvenuto, M., Nardozi, D., Angiolini, V., Mancini, P., Masuelli, L., Bei, R., Frajese, G. V., Matricardi, P., et al. (2023) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2023.120900 · Cited by 23
Liu, S., Lan, B., Wang, Y., Yang, T., Li, L., Ge, H., Zeng, C., Xu, B., Qian, H., & Ma, F. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105379 · Cited by 23
Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
Advani, P. P., Cornell, L. F., Chumsri, S., & Moreno‐Aspitia, A. (2015) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s90627 · Cited by 29
Chow, L., Suen, D. T. K., Kuen, K., & Kwong, A. (2015) · Asian Journal of Surgery · doi:10.1016/j.asjsur.2015.03.003 · Cited by 22
PIK3CA mutations in HER2-positive breast cancer: an ongoing conundrum
Goel, S., & Krop, I. E. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw246 · Cited by 25
Adamczyk, A., Grela-Wojewoda, A., Domagała-Haduch, M., Ambicka, A., Harazin-Lechowska, A., Janecka, A., Cedrych, I., Majchrzyk, K., Kruczak, A., Ryś, J., et al. (2016) · Journal of Cancer · doi:10.7150/jca.16239 · Cited by 22
Shi, K., Fang, Y., Gao, S., Yang, D., Bi, H., Xue, J., Lu, A., Li, Y., Ke, L., Lin, X., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.04.023 · Cited by 22
Pernas, S., Petit, A., Climent, F., Paré, L., Pérez-Martín, J., Ventura, L., Bergamino, M. A., Galván, P., Falo, C., Morilla, I., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00707 · Cited by 24
Han, W., Shi, L., Xie, B., Wan, J., Ren, L., Wang, Y., Chen, X., & Wang, H. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b20178 · Cited by 22
Bae, S. J., Kim, J. H., Ahn, S. G., Jeung, H., Sohn, J., Kim, G. M., Kim, M. H., Kim, S. I., Park, S., Park, H. S., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.689587 · Cited by 24
Self-citationEthier, J.-L., Desautels, D. N., Robinson, A. G., Amir, E., Kong, W., & Booth, C. M. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.2140 · Cited by 22
Rubovszky, G., Kocsis, J., Boér, K., Chilingirova, N. P., Dank, M., Kahán, Z., Kaidarova, D., Kövér, E., Vertáková-Krakovská, B., Máhr, K., et al. (2022) · Pathology & Oncology Research · doi:10.3389/pore.2022.1610383 · Cited by 24
Tran, T., Diniz, M. O., Dransart, E., Gey, A., Merillon, N., Lone, Y. C., Godefroy, S., Sibley, C., Ferreira, L. C. D. S., Médioni, J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0044 · Cited by 22
Metadata
- Authors
- Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Heeson, S., Clark, E., Ross, G., Benyunes, M. C., & Cortés, J.
- Affiliations
- MedStar Washington Hospital Center (US)
- Asan Medical Center (KR)
- National Cancer Center (KR)
- Institute of Oncology NN Petrov (RU)
- Hospital Universitario 12 De Octubre (ES)
- Centre Antoine Lacassagne (FR)
- University Hospital Heidelberg (DE)
- Roche (United Kingdom) (GB)
- Genentech (US)
- Vall d'Hebron Hospital Universitari (ES)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-02-19
- Volume
- 372
- Issue
- 8
- Pages
- 724-734
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5584549
- OpenAlex
- W2137228442
- Cited by
- 2,164
- References
- 26
- Citations by year
- 2026: 138 · 2025: 150 · 2024: 157 · 2023: 197 · 2022: 191 · 2021: 212 · 2020: 206 · 2019: 217 · 2018: 202 · 2017: 207 · 2016: 197 · 2015: 87
- FWCI
- 100.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Tampere University Institutional Repository (Tampere University) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Tampere University Institutional Repository (Tampere University) (submittedVersion)
- Funders
- F. Hoffmann-La Roche
- Genentech
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Keywords
- pertuzumab, trastuzumab, docetaxel, HER2-positive breast cancer, metastatic breast cancer, overall survival, progression-free survival, duration of response, cardiac safety, HER2-targeted therapy, first-line chemotherapy
- MeSH terms
- Trastuzumab, Docetaxel, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Double-Blind Method, Female, Humans, Infusions, Intravenous, Middle Aged, Neoplasm Metastasis, Survival Analysis, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Taxoids, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.